Critical analysis of the 2023 ESC guidelines on cardiomyopathy management

Area of Science:

• Cardiology
• Genetics
• Medical Guidelines

Background:

• The European Society of Cardiology (ESC) previously lacked comprehensive, consolidated guidelines for cardiomyopathies (CMPs).
• Managing diverse CMPs required a systematic and unified approach.
• Existing approaches to CMP classification and management were fragmented.

Purpose of the Study:

• To present the key aspects and relevance of the first ESC guidelines on cardiomyopathy management.
• To highlight the shift towards a systematic, phenotype-first approach to CMPs.
• To underscore the integration of advanced diagnostics and personalized medicine in CMP care.

Main Methods:

• Systematic review and consolidation of existing knowledge on CMPs.
• Development of a phenotype-first classification system for CMPs (hypertrophic, dilated, arrhythmogenic, restrictive, non-dilated left ventricular).
• Incorporation of genetic testing and cardiac magnetic resonance imaging (CMR) for refined diagnosis and risk stratification.

Main Results:

• The ESC guidelines provide a comprehensive, single-document framework for managing all CMPs.
• A phenotype-first categorization is recommended, though some classifications remain controversial (e.g., arrhythmogenic right ventricular CMP, non-dilated left ventricular CMP).
• Genetic testing and CMR are crucial for diagnosis, treatment decisions, and managing high-risk genotypes.

Conclusions:

• The ESC guidelines represent a significant advancement in cardiomyopathy management, offering a structured and integrated approach.
• Personalized, multidisciplinary care is advocated, leveraging genetic and imaging data.
• The guidelines acknowledge the evolving nature of CMP understanding and management.